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Background Epidemiological data link low dietary calcium with
pre-eclampsia. Current recommendations are for 1.5–2 g/day
calcium supplementation for low-intake pregnant women, based
on randomised controlled trials of ≥1 g/day calcium
supplementation from 20 weeks of gestation. This is problematic
logistically in low-resource settings; excessive calcium may be
harmful; and 20 weeks may be too late to alter outcomes.
Objectives To review the impact of lower dose calcium
supplementation on pre-eclampsia risk.
Search strategy and selection criteria We searched PubMed and
the Cochrane Pregnancy and Childbirth Group trials register.
Data collection and analysis Two authors extracted data from
eligible randomised and quasi-randomised trials of low-dose
calcium (LDC, <1 g/day), with or without other supplements.
Main results Pre-eclampsia was reduced consistently with LDC
with or without co-supplements (nine trials, 2234 women, relative
risk [RR] 0.38; 95% confidence interval [95% CI] 0.28–0.52), as
well as for subgroups: LDC alone (four trials, 980 women, RR
0.36; 95% CI 0.23–0.57]); LDC plus linoleic acid (two trials, 134
women, RR 0.23; 95% CI 0.09–0.60); LDC plus vitamin D (two
trials, 1060 women, RR 0.49; 0.31–0.78) and a trend for LDC plus
antioxidants (one trial, 60 women, RR 0.24; 95% CI 0.06–1.01).
Overall results were consistent with the single quality trial of LDC
alone (171 women, RR 0.30; 95% CI 0.06–1.38). LDC plus
antioxidants commencing at 8–12 weeks tended to reduce
miscarriage (one trial, 60 women, RR 0.06; 95% CI 0.00–1.04).
Conclusions These limited data are consistent with LDC reducing
the risk of pre-eclampsia; confirming this in sufficiently powered
randomised controlled trials would have implications for current
guidelines and their global implementation.
Keywords Calcium replacement, calcium supplement, eclampsia,
low-dose calcium, pre-eclampsia.
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Introduction
The hypertensive disorders of pregnancy cause maternal and
perinatal death.1 Strategies to reduce the risk of hypertensive
disorders of pregnancy are a global priority. Although
pre-eclampsia is disproportionately prevalent in poor com-
munities, an unexpectedly low prevalence was reported in
Ethiopian and Guatemalan women with high levels of dietary
calcium.2,3 Epidemiological, clinical and laboratory evidence
suggests a role of dietary calcium deficiency in hypertensive
disorders of pregnancy. In 2011 the World Health Organiza-
tion recommended calcium supplementation with 1.5–2.0 g
elemental calcium daily for pregnant women in areas with
low dietary calcium.4 This recommendation was based on
the evidence available from systematic reviews of randomised
clinical trials, but raises several concerns.4
To date, systematic reviews have been limited to trials
using high-dose calcium supplementation (1 g calcium/day
*Including Bergel E, Cormick G, Hall DR, Fawcus S, Lazaga Betran AP,
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or more), and excluded trials using smaller dosages.
However, 1.5–2 g calcium/day exceeds the recommended
daily allowance (RDA) of 1–1.3 g. Logistically, this dosage is
heavy to transport: 1.5 g calcium-containing calcium car-
bonate plus glycine tablets weigh about 1 kg for a 20-week
daily supply. For every 1000 pregnant women seen, 1000 kg
of tablets is required. Ingesting three large tablets daily may
be a barrier to compliance. Calcium is moderately expensive:
the cost of chewable calcium carbonate tablets without vita-
min D is $US 3–6/pregnancy (compared with $US 0.48 for
iron supplementation).5 Calcium decreases iron absorption
at doses of calcium >800 mg/day.5
Differences in dietary calcium intake between low-in-
come and high-income countries approximate 500 mg.
Typical daily intake in low-income countries ranges
between 300 and 600 mg/day, compared with 855 mg
(UK) and 969 mg (France).6
Excessive calcium supplementation may be harmful. The
evidence for harm from excessive calcium is not conclusive.
Calcium supplementation (but not dietary calcium) has
been associated with myocardial infarction risk, but this
Heidelberg study observation is at risk of confounding.7
Administration of 1.5 g calcium/day during pregnancy may
cause rebound postnatal bone demineralisation (this
Gambian finding is one of multiple comparisons and
contrary to the a priori hypothesis)8 and we identified an
unexpected increase in the syndrome of haemolysis, ele-
vated liver enzymes and low platelets (HELLP) following
calcium supplementation,9 perhaps through the antihyper-
tensive effect of calcium masking the evolution of mild
pre-eclampsia into HELLP syndrome (one of multiple
comparisons).10
Although not conclusive, the possibility of adverse effects
justifies efforts to determine the lowest effective dose of
calcium supplementation (perhaps better considered to be
calcium replacement up to the RDA) to reduce the effects
of pre-eclampsia.
In view of the above concerns, we reviewed randomised
trials of lower dosages of calcium supplementation in
pregnancy (<1 g daily).
Methods of the review
We searched the Cochrane Pregnancy and Childbirth
Database for randomised trials of low-dose (<1 g/day) cal-
cium supplementation during pregnancy, which included
pre-eclampsia as an outcome, as well as searching PubMed
for the terms ‘calcium AND (eclampsia OR pre-eclampsia
OR hypertension) AND pregnancy AND (trial OR random)’.
We planned to include in the initial analysis, trials that
met the following criteria: calcium supplementation with-
out any co-supplements; random allocation with secure
allocation concealment; and double blinding with placebo.
If the above criteria failed to produce adequate data, we
planned to include data from quasi-randomised trials, trials
without placebo control and trials of multiple supplements,
with appropriate caution in the interpretation of such data.
We sought the following outcomes: pre-eclampsia;
maternal death or serious morbidity; placental abruption;
caesarean section; proteinuria; severe pre-eclampsia, as
defined by trial authors; eclampsia; HELLP syndrome;
intensive care unit admission; maternal death; maternal
hospital admission ≥7 days; low birthweight (first weight
obtained after birth <2500 g); neonate small-for-gestational
age as defined by trial authors; neonate in intensive care
unit for 7 days or more; death or severe neonatal morbid-
ity; childhood disability; systolic blood pressure greater
than 95th centile during childhood; and diastolic blood
pressure greater than 95th centile during childhood.
Two authors assessed the risk of bias and extracted data
from the original papers or translations of papers other
than those in English using a purpose-designed data
extraction form. We expressed outcomes as summary risk
ratios with 95% confidence intervals (95% CI), using the
Mantel–Haenszel method with a fixed effect model
(REVMAN software, Information Management System,
Nordic Cochrane Centre, Copenhagen, Denmark). If there
was significant heterogeneity we used a random effects
model. Risk of bias was based on the adequacy of reported
allocation concealment, and was categorised as: low risk of
bias (e.g. telephone or central randomisation; consecutively
numbered sealed opaque envelopes); or high risk of bias
(open random allocation; unsealed or non-opaque
envelopes, alternation; date of birth, or method not stated).
Results
The PubMed search (17 September 2012) identified 201
papers, and the Cochrane Pregnancy and Childbirth Trials
Register identified 51 trials, of which nine met the criteria
for inclusion in this review (Figure 1). One trial included a
comparison that met our primary inclusion criteria (low
risk of bias, low-dose calcium compared with no
calcium).11 Both groups from this trial included in the
review received low-dose aspirin as a co-intervention. Six
trials did not report adequate allocation concealment strate-
gies (high risk of bias), of which three used calcium alone12–
14 and two used calcium plus Vitamin D.15,16 One trial with
low risk of bias used calcium plus antioxidants17 and two tri-
als with low risk of bias used calcium plus linoleic acid.18,19
The details of the included trials are shown in Table 1.
The effects of the interventions are shown in Table 2 and
Figure 2. The four trials at low risk of bias, all in women
at high risk of pre-eclampsia, showed a consistent reduc-
tion in pre-eclampsia (365 women, risk ratio 0.25; 95% CI
0.12–0.50). However, in three of these trials there was
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co-intervention with linoleic acid (two trials) or antioxi-
dants.
Discussion
Main findings
Trials of low-dose calcium supplementation in women at
high risk of pre-eclampsia, without or with linoleic acid or
antioxidants, report a reduction in pre-eclampsia similar to
that shown in the trials of high-dose calcium supplementa-
tion in women at high risk of pre-eclampsia. Whether the
effect in the trial with antioxidants can be attributed in
part to the antioxidants is unlikely, as a systematic review
found that antioxidants do not reduce the risk of
pre-eclampsia.20 We are not aware of robust evidence
regarding possible effects of linoleic acid on pre-eclampsia.
Limitations
Due to the limitations of the studies included (which
included trials with concurrent antioxidant administration),
the findings of this review should not be regarded as con-
clusive. However, they are consistent with the possibility of
a beneficial effect of low-dose calcium supplementation
during pregnancy, and, therefore, highlight the need for
methodologically sound, sufficiently powered trials to either
confirm or refute this effect.
Interpretation
The findings of this review, although studying calcium sup-
plementation in late pregnancy, rather than before preg-
nancy and in early pregnancy, support our principle of
studying lower-dose calcium supplementation in relation to
the hypertensive disorders of pregnancy. Currently, we are
conducting a trial of low-dose calcium supplementation
(500 mg/day) in women with previous pre-eclampsia, com-
mencing before pregnancy and continuing for up to
20 weeks of pregnancy.8 The choice of the dose of calcium
was based on practical considerations: if calcium supple-
mentation before and in early pregnancy is found to have
an important effect on the development of pre-eclampsia,
the only viable way of implementing the intervention at a
community level would be with food fortification. The
dosage of 500 mg would be achievable with fortification of
calcium-poor staple foods, without exposing the general
population to levels of dietary calcium in excess of the
RDA. Food calcium fortification is seen as a relevant strat-
egy not only for prevention of pre-eclampsia but also for
bone health and for lowering the risk of other disorders
such as hypertension, colon cancer and obesity.10
The RDA for calcium intake during pregnancy has been a
subject of controversy. Based on considerations of fetal needs
and high calcium urinary output in pregnancy, historical fig-
ures for calcium intake as high as 2 g/day have been pro-
posed to obtain a positive balance during pregnancy.21
However, it has been reported that calcium absorption in
pregnancy reaches levels twice as high as those seen in non-
pregnant women.22 The current National Institutes of Health
(NIH) RDA for pregnant women aged 14–18 years is
1300 mg, and 1000 mg for pregnant women aged 19–
50 years.23 Health Canada RDA replicates NIH, and The Sin-
gapore Health Promotion Board RDA for calcium during
pregnancy is 1000 mg. Reduced dietary calcium intake below
the RDA is associated with hypertension outside preg-
nancy,24 as well as osteoporosis, renal stones, increased body
mass index, insulin resistance and colorectal cancer.
It should be recognised that the epidemiological associa-
tion of pre-eclampsia with low dietary calcium is not evi-
dence of a direct causal link. Efforts to confirm such a link
have focused on randomised trials of calcium supplementa-
tion during pregnancy, commencing in the late 1980s.
Previously, we conducted a systematic review of
randomised trials of calcium supplementation of at least
1 g daily during pregnancy.9 This review discussed the
epidemiological, clinical and laboratory studies linking
pre-eclampsia with dietary calcium deficiency. The results
of the review showed inconsistency between the trials in
women at high and low risk of pre-eclampsia. The risk
ratio (RR) for pre-eclampsia for trials in women at high
risk of pre-eclampsia was 0.22 (95% CI 0.12–0.42). The
risk ratio for trials in women at low risk was 0.59 (95%
CI 0.41–0.83). The results of the review were dominated
by the WHO trial of calcium supplementation among
low-calcium-intake pregnant women conducted in
2001–03.10 Results from this trial showed that although
Identified by Cochrane search: 51
↓
Did not meet inclusion criteria: 27
↓
Trials of high dose calcium: 15
↓
Trials of low-dose calcium (included): 9
No additional relevant trials were identified from 201 papers identified from the Pubmed search.
Figure 1. Flow diagram of study selection.
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Table 1. Features of the included studies
Study Methods Participants Interventions included in this
review
Risk of
bias
Almirante
(1998)16
‘divided into two groups
and followed up until
delivery’
430 nulliparous pregnant women
who were adolescents and elderly
(High risk of pre-eclampsia)
500 mg elemental calcium from
16 to 20 weeks till delivery
versus controls
High
Bassaw (1998)15 Randomisation using a
table of random
numbers, supplements
were distributed in
sealed envelopes.
Pregnant women recruited before
20 weeks of gestation,
primigravidae, or multigravidae
with obstetric history of
pre-eclampsia. No underlying
medical disorders. (High risk of
pre-eclampsia). Setting: Trinidad,
women of African, East Indian and
mixed ethnicity.
Included in this review: 600 mg
elemental calcium plus 80 mg
aspirin daily versus 80 mg
aspirin (other groups studied
were control and high-dose
calcium alone).
Low
Cong (1995)17 ‘randomised and divided
into 3 groups’
Healthy primiparous women
(Low risk of pre-eclampsia)
120 mg calcium daily versus
240 mg calcium daily
(combined in this analysis)
versus no calcium
High
Herrera (1998)22 Allocated to active tablets
or identical-looking
placebo by means of
sequentially numbered,
sealed allocation cards
in computer-generated
random sequence.
Primigravidas with risk factors for
pre-eclampsia, positive roll-over test
and high mean blood pressure; low
dietary calcium (High risk of pre-
eclampsia). Setting: Colombia,
black and mixed race women,
socio-economic levels 1 and 2.
450 mg linoleic acid plus
600 mg calcium versus
placebo in the third trimester
Low
Herrera (2006)23 Allocated to active tablets
or identical-looking
placebo by means of
sequentially numbered,
sealed allocation cards
in computer-generated
random sequence.
Primigravidas <19 years or >35 years
old, with risk factors for pre-
eclampsia, abnormal uterine artery
Doppler ultrasound, low dietary
calcium (High risk of pre-
eclampsia). Setting: Bangladesh
and Colombia. Median daily dietary
calcium 602 in the calcium group
and 576 in the placebo group.
450 mg conjugated linoleic acid
plus 600 mg calcium versus
placebo from 18 to 22 weeks
until delivery
Low
Marya (1987)19 ‘Randomly selected’ Pregnant women 20–35 years
old, low dietary calcium
(Low risk of pre-eclampsia)
Calcium 375 mg plus Vit D
1200 IU from 20 to 24 weeks
of pregnancy onwards versus
control
High
Rogers (1999)18 Randomised in ratio 1:2:2
using five unsealed
envelopes, selected by
participants
Primiparous women in second
trimester with rested left lateral
automated blood pressureBP MAP
60 mmHg or more (Low risk of
pre-eclampsia)
Calcium 600 mg daily from 22
to 32 weeks, then 1200 mg
daily versus controls
High
Rumiris (2006)21 Double-blind, placebo-
controlled trial.
Randomised according
to a computer-
generated random
number sequence by
an independent third
party.
Pregnant women with low
antioxidant status at 8–12 weeks
of gestation. No medical
complications or current use of trial
supplements. (High risk of
pre-eclampsia). Setting, antenatal
clinic, University of Indonesia.
Calcium 800 mg,
N-acetylcysteine 200 mg, copper
2 mg, zinc 15 mg,
manganese 0.5 mg, and
selenium 100 lg and vitamins
A 1000 IU, B6 2.2 mg, B12 2.2 lg,
C 200 mg and E 400 IU, from 8 to
12 weeks of gestation throughout
pregnancy.
Low
Taherian (2002)20 ‘randomised and divided
into 3 groups’
Healthy nulliparous women (Low
risk of pre-eclampsia)
500 mg calcium + 200 IU vitamin D
from 20th week of pregnancy till
delivery versus control
High
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1.5 g calcium/day in the second half of pregnancy did not
prevent pre-eclampsia (RR 0.92, 95% CI 0.75–1.13), there
was a significant reduction in the outcome maternal death
or severe morbidity (RR 0.80, 95% CI 0.65–0.97),
including a trend to fewer deaths with calcium supple-
mentation (1/4151 versus 6/4161 women).
Other reviews have concluded that calcium supplementa-
tion is an effective intervention to reduce pre-eclampsia,11
neonatal mortality and preterm birth in developing
countries.25
In addition, we have reported that high-dose calcium
supplementation in pregnancy reduces the serious adverse
effects of pre-eclampsia, but has no effect on markers for
pre-eclampsia (proteinuria, platelet counts or urate levels).7
We proposed the hypothesis that calcium supplementation
in the second half of pregnancy might reduce blood
pressure and, therefore, the serious complications of this
component of pre-eclampsia without affecting other
components of the syndrome or the underlying pathology
related to placental development, and that calcium supple-
mentation before and in early pregnancy might affect this
process.25
Indirect evidence that supra-physiological doses of
calcium may not improve outcomes above physiological
dosages is given by the large CPEP study (4589 women),
which compared calcium 2 g daily versus placebo in
women with normal calcium intake. Actual median intakes
were 2369 g in the calcium group versus 982 g with
placebo. This additional supplementation of women with
normal dietary calcium had no statistically significant effect
on pre-eclampsia. In addition, we have outlined the caveats
around high-dose calcium supplementation related to the
Heidelberg and Gambian studies, above.7,8
Conclusions
We have not identified robust evidence related to the effect
of low-dose calcium supplementation in pregnancy on
pre-eclampsia and related outcomes. The available evidence
is consistent with a reduction in the risk of pre-eclampsia.
Confirmation of this possible effect in sufficiently powered,
robust randomised trials would have major implications
for the current WHO guidelines and their implementation
in low-income countries.
Table 2. Results of meta-analysis of trials with low risk of bias
Outcome or subgroup Studies Participants Effect estimates*
High blood pressure 2 219 0.42 (0.20–0.87)
Calcium supplementation alone 1 171 0.60 (0.25–1.46)
Calcium plus linoleic acid 1 48 0.20 (0.05–0.82)
Pre-eclampsia 4 365 0.25 (0.12–0.50)
Calcium supplementation alone 1 171 0.30 (0.06–1.30)
Calcium plus linoleic acid 2 134 0.23 (0.09–0.60)
Calcium plus antioxidants 1 60 0.24 (0.06–1.01)
Caesarean section 2 134 0.55 (0.34–0.86)
Calcium plus linoleic acid 2 134 0.55 (0.34–0.86)
Severe pre-eclampsia 2 146 0.34 (0.10–1.21)
Calcium plus linoleic acid 1 86 0.33 (0.07–1.56)
Calcium plus antioxidants 1 60 0.36 (0.04–3.23)
Preterm birth 2 108 0.41 (0.08–2.05)
Calcium plus linoleic acid 1 48 0.50 (0.05–5.15)
Calcium plus antioxidants 1 60 0.36 (0.04–3.23)
Birthweight <2500 g 2 134 0.20 (0.05–0.88)
Calcium plus linoleic acid 2 134 0.20 (0.05–0.88)
Neonate small for gestational age 3 194 0.38 (0.10–1.38)
Calcium plus linoleic acid 2 134 0.29 (0.06–1.32)
Calcium plus antioxidants 1 60 1.07 (0.07–16.31)
Stillbirth or death before discharge 4 365 0.61 (0.15–2.53)
Calcium supplementation alone 1 171 1.04 (0.07–16.29)
Calcium plus linoleic acid 2 134 0.60 (0.08–4.41)
Calcium plus antioxidants 1 60 0.36 (0.02–8.39)
Miscarriage (not prespecified) 1 60 0.06 (0.00–1.04)
Calcium plus antioxidants 0.06 (0.00–1.04)
Low-dose calcium supplementation (<1 g/day) with or without co-supplements.
*Effect estimates expressed as risk ratio (95% CI), Mantel–Haenszel method, fixed effects model.
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Currently, the logistics and cost of the WHO recommen-
dation for supplementation with 1.5–2 g calcium daily have
been regarded as prohibitive in several settings (Smith JM.
[Internet]. E-mail to Diane Sawchuck. 2012 December 12
[cited 2013 Feb 12]). The dilemma facing health
policymakers in these settings is whether supplementation
with a lower dose would be better than no supplementa-
tion at all. The findings of this review and commentary
provide limited evidence on which to base such decisions,
but further research is needed.
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